Literature DB >> 17476276

Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.

A Tefferi, J J Strand, T L Lasho, R A Knudson, C M Finke, N Gangat, A Pardanani, C A Hanson, R P Ketterling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17476276     DOI： 10.1038/sj.leu.2404724

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  22 in total

1.  Clinical relevance of JAK2 (V617F) mutant allele burden.

Authors:  Francesco Passamonti; Elisa Rumi
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

2.  JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.

Authors:  Koichi Takahashi; Keyur P Patel; Hagop Kantarjian; Rajyalakshmi Luthra; Sherry Pierce; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2013-09-25       Impact factor: 22.113

3.  A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves.

Authors:  Philippe Szankasi; N Scott Reading; Cecily P Vaughn; Josef T Prchal; David W Bahler; Todd W Kelley
Journal:  J Mol Diagn       Date:  2013-01-08       Impact factor: 5.568

4.  Polycythemia vera: gender-related phenotypic differences.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro; Maria Anna Nicolazzi; Igor Giarretta; RosaMaria Marfisi; Roberto Marchioli
Journal:  Intern Emerg Med       Date:  2011-06-10       Impact factor: 3.397

5.  New and old prognostic factors in polycythemia vera.

Authors:  Francesco Passamonti
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

6.  JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.

Authors:  Richard T Silver; Katherine Vandris; Y Lynn Wang; Fernando Adriano; Amy V Jones; Paul J Christos; Nicholas C P Cross
Journal:  Leuk Res       Date:  2010-07-22       Impact factor: 3.156

7.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

8.  JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Chiara M Dellacasa; Silvia Salmoiraghi; Federica Delaini; Alessandro Rambaldi; Tiziano Barbui
Journal:  Exp Hematol       Date:  2009-06-24       Impact factor: 3.084

9.  The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park
Journal:  Blood Res       Date:  2013-06-25

10.  Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Authors:  Jung-Sook Ha; Yu-Kyung Kim; Soon-Il Jung; He-Ra Jung; In-Sung Chung
Journal:  Ann Lab Med       Date:  2012-10-17       Impact factor: 3.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.